Meridith Unger

Meridith is a graduate of Harvard Business School, where she was a member of the Venture Creation Program. Meridith earned her AB from Bryn Mawr College where she received the Anna Pell Wheeler Prize for Mathematics, and minored in Art History.

As a Blavatnik Fellow and Entrepreneur-In-Residence at Harvard Business School, Meridith works with healthcare and wearable technology startups, crafting and executing on strategic plans to carry high-potential technologies from pre-inception through Series A. Meridith has worked closely with and for several venture capital firms, including Third Rock Ventures, Lux Capital, Oxford BioScience Partners, and the Technology Development Fund—an academic venture fund at Boston Children's Hospital, as well as independently. During this time she was involved, in the creation and development of several NewCos, including FlexLite, Lumos Catheter Systems, Sage Therapeutics, AviTx Inc, Kala Pharmaceuticals, and Asterand. 

​

Meridith was also the co-founder and CEO of Aukera Therapeutics, which won the Life Sciences Track and the Audience Choice Awards in the 2010 MIT $100K Competition, and was a finalist for MassChallenge in their inaugural session in 2010. 

​

Prior to her work in venture capital and entrepreneurship, Meridith was a Managing Consultant with Boston Healthcare Associates and a Senior Associate with Silicon Valley Bank's Life Sciences and Venture Capital Lending Group.

A member of Class 15, Meridith began her fellowship with Atlas Venture and continued the program through the sponsorship of the Technology Development Fund at Children's Hospital Boston. Her mentors were Peter Barrett and Erik Halvorsen, respectively.